The global surgical site infection control market size reached US$ 4.4 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 5.7 Billion by 2028, exhibiting a growth rate (CAGR) of 4.1% during 2023-2028.
Surgical site infection (SSI) control refers to various practices or measures employed to prevent infections among patients during their stay at the hospital. These infections occur after surgery in the operated part of the body, leading to poor wound healing and extended overnight stays for the treatment. SSI control is essential as these infections can be severe and affect tissues, organs, or implants. Some commonly used SSI control products include surgical drapes, gloves, hair covers, disinfectants, skin preparation solutions, scrubs, and medical nonwovens. In recent years, SSI control solutions have gained traction across the healthcare sector as they help prevent infections, enhance patient care quality, and improve surgical outcomes and success rates.
Surgical Site Infection Control Market Trends:
SSI control products assist in reducing the duration of hospital stays, eliminating the need for revision surgeries, and minimizing patient discomfort. As a result, the rising cases of hospital-acquired infections represent the primary factor driving the market growth. Besides this, the growing awareness regarding SSIs and the shifting focus toward infection prevention through proper control measures are augmenting the product demand. Additionally, there has been a significant increase in the prevalence of chronic conditions, such as cancer, gastrointestinal disorders, and cardiovascular diseases (CVDs), due to the aging population, sedentary lifestyles, and unhealthy eating habits. This, in confluence with the increasing number of patients undergoing surgical procedures, is accelerating the adoption of SSI control products. Furthermore, several favorable initiatives undertaken by the governing and non-governing agencies of various countries, such as the introduction of stringent guidelines and training programs focused on infection control practices, are catalyzing the market growth. Moreover, the rising integration of SSI control products with advanced technologies, improving healthcare infrastructure, and ongoing research and development (R&D) activities are some of the factors creating a positive market outlook.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global surgical site infection control market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on product, infection type, surgery type and end user.
Breakup by Product:
- Antibiotic Prophylaxis Products
- Wound Care Dressings
- Surgical Drapes
- Surgical Clippers
- Antiseptics and Disinfectants
- Wound Irrigation Products
Breakup by Infection Type:
- Superficial Incisional SSI
- Deep Incisional SSI
- Organ or Space SSI
Breakup by Surgery Type:
- Cesarean Section
- Gastric Bypass
- Cataract Surgery
- Dental Restoration
Breakup by End User:
- Ambulatory Surgical Centers
Breakup by Region:
- North America
- South Korea
- United Kingdom
- Latin America
- Middle East and Africa
The competitive landscape of the industry has also been examined along with the profiles of the key players being 3M Company, Ansell Limited, Becton Dickinson and Company, bioMerieux SA. (Institut Mérieux), Covalon Technologies Ltd., GAMA Healthcare Ltd., Getinge AB (Carl Bennet AB), Johnson & Johnson, Kimberly-Clark Corporation, Mölnlycke Health Care AB, Prescient Surgical, Steris Corporation, etc.
|Base Year of the Analysis
| Historical Period
||Product, Infection Type, Surgery Type, End User, Region
|| Asia Pacific, Europe, North America, Latin America, Middle East and Africa
||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico
||3M Company, Ansell Limited, Becton Dickinson and Company, bioMerieux SA. (Institut Mérieux), Covalon Technologies Ltd., GAMA Healthcare Ltd., Getinge AB (Carl Bennet AB), Johnson & Johnson, Kimberly-Clark Corporation, Mölnlycke Health Care AB, Prescient Surgical, Steris Corporation
||10% Free Customization
|Report Price and Purchase Option
||Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499
|Post-Sale Analyst Support
||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)
Key Questions Answered in This Report:
- How has the global surgical site infection control market performed so far and how will it perform in the coming years?
- What has been the impact of COVID-19 on the global surgical site infection control market?
- What are the key regional markets?
- What is the breakup of the market based on the product?
- What is the breakup of the market based on the infection type?
- What is the breakup of the market based on the surgery type?
- What is the breakup of the market based on the end user?
- What are the various stages in the value chain of the industry?
- What are the key driving factors and challenges in the industry?
- What is the structure of the global surgical site infection control market and who are the key players?
- What is the degree of competition in the industry?